# Noel Greenberger

> Noel Greenberger is the CEO of Nob Hill Therapeutics, an Albuquerque-based respiratory company building DryNeb, a dry powder nebulizer that pushes high therapeutic doses deep into the lungs regardless of a patient's breathing capacity. A Wharton MBA and Northwestern-trained industrial engineer, he spent years commercializing respiratory medicines at Sandoz, ran commercial strategy at Vertice Pharma, and consulted at McKinsey and ZS Associates before taking the helm of Nob Hill in 2022. Under his watch the company won a $1.73M HHS Phase II grant and closed a $3M Series A in 2024.

- **Role:** Chief Executive Officer at Nob Hill Therapeutics
- **Organizations:** Nob Hill Therapeutics, Vertice Pharma, Sandoz (Novartis), McKinsey & Company, ZS Associates
- **Nationality:** American
- **Education:** Master of Business Administration (MBA), The Wharton School, University of Pennsylvania, B.S. in Industrial Engineering, Northwestern University
- **Known for:** Appointed CEO of Nob Hill Therapeutics in 2022 after serving on its advisory board, Secured a U.S. HHS Phase II grant of up to $1.73 million to develop an inhaled dry powder antifungal on the DryNeb platform, Closed a $3 million Series A financing in August 2024 led by Tramway Venture Partners

## Career timeline

- **Early career** — Consultant at ZS Associates, focused on pharmaceutical sales and marketing strategy
- **Mid career** — Consultant in the healthcare practice at McKinsey & Company
- **At Sandoz** — Leadership roles in biopharmaceuticals and strategic planning, then Executive Director of Respiratory at Sandoz U.S., building and commercializing its respiratory medicines portfolio
- **At Vertice** — Chief Commercial Officer at Vertice Pharma, a private equity-backed specialty pharmaceutical company
- **2021** — Joined Nob Hill Therapeutics' strategic advisory board
- **2022** — Named CEO of Nob Hill Therapeutics (effective September 1, 2022); company wins HHS Phase II grant of up to $1.73M for a nebulized dry powder antifungal
- **2024** — Led Nob Hill through a $3M Series A round backed by Tramway Venture Partners, TCA Venture Group, and VIC Technology Venture Development
- **2025** — Expanded Nob Hill's strategic advisory board with respiratory and pulmonary specialists Dr. Mark Parry-Billings and Dr. Scott L. Shofer

## Achievements

- Appointed CEO of Nob Hill Therapeutics in 2022 after serving on its advisory board
- Secured a U.S. HHS Phase II grant of up to $1.73 million to develop an inhaled dry powder antifungal on the DryNeb platform
- Closed a $3 million Series A financing in August 2024 led by Tramway Venture Partners
- Built and commercialized a respiratory medicines portfolio as Executive Director of Respiratory at Sandoz U.S.
- Served as Chief Commercial Officer at Vertice Pharma

## Latest updates

- **2025-06** — Nob Hill Therapeutics expanded its strategic advisory board with Dr. Mark Parry-Billings and Dr. Scott L. Shofer.
- **2024-08** — Nob Hill Therapeutics closed a $3M Series A led by Tramway Venture Partners.

## Links

- Website: https://nobhilltherapeutics.com
- LinkedIn: https://www.linkedin.com/in/noel-greenberger-616b0a3/

---

Profile page: https://yespress.io/noel-greenberger
Published by YesPress — https://yespress.io
Last updated: 2026-07-01